Amneal Pharmaceuticals
AMRX
237 hedge funds and large institutions have $1.14B invested in Amneal Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 91 increasing their positions, 54 reducing their positions, and 14 closing their positions.
271% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 14
168% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $1.19M
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
69% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 54
19% more funds holding
Funds holding: 199 → 237 (+38)
14% more capital invested
Capital invested by funds: $999M → $1.14B (+$139M)
2.63% more ownership
Funds ownership: 40.7% → 43.33% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$7.82M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.69M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$7.35M |
| 4 |
Millennium Management
New York
|
+$6.37M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.4M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.33M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$2.69M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$2.27M |
| 5 |
HAI
Hennessy Advisors Inc
Novato,
California
|
-$1.43M |
AMRX Hedge Fund Activity: Q1 2025 in Review
237 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2025, worth a combined $1.14B — up 14% from $999M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new AMRX positions and 14 closed out — a net gain of 38 holders — while 91 added to existing stakes and 54 trimmed.
The largest buyer was Woodline Partners, adding an estimated $7.82M. The largest seller was Citadel Advisors, cutting an estimated $12.4M.
- 237 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2025, up from 199 in Q4 2024.
- Funds reported $1.14B of Amneal Pharmaceuticals stock for Q1 2025, up 14% quarter-over-quarter.
- 52 funds opened new Amneal Pharmaceuticals positions in Q1 2025 and 14 closed out, a net change of +38 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2025 was Woodline Partners, an estimated $7.82M added.
- The largest Amneal Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2025.